Phase I Dose Escalation and Landmark Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma (UTUC) Following Endoscopic Resection.
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2016
At a glance
- Drugs Valrubicin (Primary)
- Indications Urogenital cancer
- Focus Adverse reactions
- 21 Apr 2016 Status changed from active, no longer recruiting to completed.
- 03 Dec 2015 Planned End Date changed from 1 Feb 2016 to 1 Jun 2016, according to ClinicalTrials.gov record.
- 03 Dec 2015 Planned primary completion date changed from 1 Feb 2016 to 1 Jun 2016, according to ClinicalTrials.gov record.